NEW YORK (Reuters Health) - HER-2-positive, hormone receptor-negative breast cancer patients have a high risk of treatment failure after chemotherapy -- and the most common site of cancer recurrence after treatment failure is the brain, Mayo Clinic researchers reported at the San Antonio Breast Cancer Symposium.Breast cancers that are estrogen-receptor and progesterone-receptor negative are associated with the worst outcomes and require aggressive treatment right from the time of diagnosis, Dr. Laura Vallow of the Mayo Clinic in Rochester, Minnesota, told Reuters Health.
